vTv Therapeutics Inc. Class A Company Profile
NASDAQ: VTVTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
vTv Therapeutics at a glance
vTv Therapeutics Inc. Class A (NASDAQ: VTVT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in High Point, NC. vTv Therapeutics is led by Mr. Paul J. Sekhri and employs about 26 people. The company's shares have traded publicly since 2015.
At a market capitalization of $118.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001641489, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does vTv Therapeutics do?
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Business description based on the company's public filings.
Company information
- Legal name
- vTv Therapeutics Inc. Class A
- Ticker
- NASDAQ: VTVT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul J. Sekhri
- Employees
- 26
- Headquarters
- 3980 Premier Drive, High Point, NC, United States
- Phone
- 336 841 0300
- Website
- vtvtherapeutics.com
- IPO year
- 2015
- Market cap
- $118.93M
- SEC CIK
- 0001641489
Companies similar to vTv Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INOInovio Pharmaceuticals Inc. | 1.15 | +5.50% | $118.91M | vs VTVT |
| FHTXFoghorn Therapeutics Inc. | 2.00 | +0.50% | $118.77M | vs VTVT |
| COYACoya Therapeutics Inc. | 4.95 | -0.80% | $116.12M | vs VTVT |
| GNLXGenelux Corporation | 2.56 | +2.40% | $115.83M | vs VTVT |
| PMVPPMV Pharmaceuticals Inc. | 1.52 | +2.01% | $114.78M | vs VTVT |
| NRXPNRX Pharmaceuticals Inc. | 2.85 | -1.38% | $123.39M | vs VTVT |
| QUCYQuantum Cyber N.V. | 1.35 | -2.88% | $113.49M | vs VTVT |
| HURATuHURA Biosciences Inc. | 1.96 | +1.55% | $124.90M | vs VTVT |